



Notice of AGM and Change of Director

October 1, 2021

RNS Number : 8000N
MaxCyte, Inc.
01 October 2021

MaxCyte, Inc.

("MaxCyte" or the "Company")

Notice of Annual General Meeting

Change of Director

Gaithersburg, Maryland - 1 October 2021: MaxCyte, Inc (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, announces that formal notice and resolutions of the Company's Annual General Meeting (AGM), have been circulated to Shareholders.

These documents are also available in electronic form on the Company's website: www.maxcyte.com.

In addition, on September 30, 2021, Dr. J. Stark Thompson notified the board of directors (the "Board") of the Company that he will not stand for re-election at the Annual Meeting of Stockholders to be held on October 29, 2021 (the "Annual Meeting"). Dr. Thompson will serve out his remaining term as a director and as Chairman of the Board, which will expire upon the conclusion of the Annual Meeting. Dr. Thompson's decision is not related to any disagreement relating to the Company's operations, policies or practices. He will continue to provide consulting services to the Company as requested, during which time his outstanding stock option awards will continue to vest in accordance with their terms for so long as Dr. Thompson provides continuous service to the Company. Following the Annual Meeting, the authorized size of the Board will be eight members, and the Board will appoint a new Chairman.

"On behalf of the Board and the entire MaxCyte team, we wish to thank Dr. Thompson for his service and guidance on the Board over the years," said Doug Doerfler, Chief Executive Officer.

For further information, please contact:

MaxCyte Contacts:

US IR Adviser

Gilmartin Group

David Deuchler, CFA

+1 415-937-5400

ir@maxcyte.com

Nominated Adviser and Joint Corporate Broker

Panmure Gordon

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

+44 (0)20 7886 2500

UK IR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

+44 (0)203 709 5700

maxcyte@consilium-

comms.com

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: three instruments, the ATx™, STx™ and GTx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOAMBBITMTIMBIB